Global Oncology Based Preclinical CRO Industry Growth and Trends Forecast to 2031

Summary

Preclinical research refers to before testing a drug in people, researchers must find out whether it has the potential to cause serious harm, also called toxicity. A Preclinical CRO, or preclinical contract research organization, provides the experience, knowledge, and skill required to take a pharmaceutical product or medical device from the drawing board to distribution. This journey entails a plethora of activities that involve scientists, medical personnel, administrators, governmental and industry liaisons, marketing experts, and a host of other technical and creative individuals. Rarely is this unique combination of credentials and craft already present within a sponsoring organization. The CRO industry emerged to fill this much-needed role, to provide the expertise required to bring a pharmaceutical product or medical device into the marketplace as quickly and smoothly as possible.

According to APO Research, The global Oncology Based Preclinical CRO market was estimated at US$ million in 2025 and is projected to reach a revised size of US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2026-2031.

North American market for Oncology Based Preclinical CRO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Asia-Pacific market for Oncology Based Preclinical CRO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

Europe market for Oncology Based Preclinical CRO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2026 through 2031.

The major global companies of Oncology Based Preclinical CRO include Crown Bioscience, Charles River, ICON, Eurofins Scientific, Taconic Biosciences, Covance, EVOTEC, The Jackson Laboratory and MI Bioresearch, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Oncology Based Preclinical CRO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Based Preclinical CRO.

The Oncology Based Preclinical CRO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oncology Based Preclinical CRO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, gross margin by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Oncology Based Preclinical CRO Segment by Company

Crown Bioscience
Charles River
ICON
Eurofins Scientific
Taconic Biosciences
Covance
EVOTEC
The Jackson Laboratory
MI Bioresearch
Champion Oncology
Wuxi AppTec.
Xentech
Living Tumor Laboratory

Oncology Based Preclinical CRO Segment by Type

Blood Cancer
Solid Tumors
Others

Oncology Based Preclinical CRO Segment by Application

In Vitro
In Vivo

Oncology Based Preclinical CRO Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oncology Based Preclinical CRO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Oncology Based Preclinical CRO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oncology Based Preclinical CRO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2020-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Oncology Based Preclinical CRO companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview

1.1 Product Definition
1.2 Global Market Growth Prospects
1.3 Global Oncology Based Preclinical CRO Market Size Overview by Region 2020 VS 2024 VS 2031
1.4 Global Oncology Based Preclinical CRO Market Size by Region (2020-2031)
1.4.1 Global Oncology Based Preclinical CRO Market Size by Region (2020-2025)
1.4.2 Global Oncology Based Preclinical CRO Market Size by Region (2026-2031)
1.5 Key Regions Oncology Based Preclinical CRO Market Size (2020-2031)
1.5.1 North America Oncology Based Preclinical CRO Market Size Growth Rate (2020-2031)
1.5.2 Europe Oncology Based Preclinical CRO Market Size Growth Rate (2020-2031)
1.5.3 Asia-Pacific Oncology Based Preclinical CRO Market Size Growth Rate (2020-2031)
1.5.4 South America Oncology Based Preclinical CRO Market Size Growth Rate (2020-2031)
1.5.5 Middle East & Africa Oncology Based Preclinical CRO Market Size Growth Rate (2020-2031)
2 Oncology Based Preclinical CRO Market by Type

2.1 Type Introduction
2.1.1 Blood Cancer
2.1.2 Solid Tumors
2.1.3 Others
2.2 Global Oncology Based Preclinical CRO Market Size by Type
2.2.1 Global Oncology Based Preclinical CRO Market Size Overview by Type (2020-2031)
2.2.2 Global Oncology Based Preclinical CRO Historic Market Size Review by Type (2020-2025)
2.2.3 Global Oncology Based Preclinical CRO Market Size Forecasted by Type (2026-2031)
2.3 Global Oncology Based Preclinical CRO Market Size by Regions
2.3.1 North America Oncology Based Preclinical CRO Market Size Breakdown by Type (2020-2025)
2.3.2 Europe Oncology Based Preclinical CRO Market Size Breakdown by Type (2020-2025)
2.3.3 Asia-Pacific Oncology Based Preclinical CRO Market Size Breakdown by Type (2020-2025)
2.3.4 South America Oncology Based Preclinical CRO Market Size Breakdown by Type (2020-2025)
2.3.5 Middle East and Africa Oncology Based Preclinical CRO Market Size Breakdown by Type (2020-2025)
3 Oncology Based Preclinical CRO Market by Application

3.1 Type Introduction
3.1.1 In Vitro
3.1.2 In Vivo
3.2 Global Oncology Based Preclinical CRO Market Size by Application
3.2.1 Global Oncology Based Preclinical CRO Market Size Overview by Application (2020-2031)
3.2.2 Global Oncology Based Preclinical CRO Historic Market Size Review by Application (2020-2025)
3.2.3 Global Oncology Based Preclinical CRO Market Size Forecasted by Application (2026-2031)
3.3 Global Oncology Based Preclinical CRO Market Size by Regions
3.3.1 North America Oncology Based Preclinical CRO Market Size Breakdown by Application (2020-2025)
3.3.2 Europe Oncology Based Preclinical CRO Market Size Breakdown by Application (2020-2025)
3.3.3 Asia-Pacific Oncology Based Preclinical CRO Market Size Breakdown by Application (2020-2025)
3.3.4 South America Oncology Based Preclinical CRO Market Size Breakdown by Application (2020-2025)
3.3.5 Middle East and Africa Oncology Based Preclinical CRO Market Size Breakdown by Application (2020-2025)
4 Global Market Dynamics

4.1 Oncology Based Preclinical CRO Industry Trends
4.2 Oncology Based Preclinical CRO Industry Drivers
4.3 Oncology Based Preclinical CRO Industry Opportunities and Challenges
4.4 Oncology Based Preclinical CRO Industry Restraints
5 Competitive Insights by Company

5.1 Global Top Players by Oncology Based Preclinical CRO Revenue (2020-2025)
5.2 Global Oncology Based Preclinical CRO Industry Company Ranking, 2023 VS 2024 VS 2025
5.3 Global Oncology Based Preclinical CRO Key Company Headquarters & Area Served
5.4 Global Oncology Based Preclinical CRO Company, Product Type & Application
5.5 Global Oncology Based Preclinical CRO Company Commercialization Time
5.6 Market Competitive Analysis
5.6.1 Global Oncology Based Preclinical CRO Market CR5 and HHI
5.6.2 Global Top 5 and 10 Oncology Based Preclinical CRO Players Market Share by Revenue in 2024
5.6.3 2024 Oncology Based Preclinical CRO Tier 1, Tier 2, and Tier 3
6 Company Profiles

6.1 Crown Bioscience
6.1.1 Crown Bioscience Comapny Information
6.1.2 Crown Bioscience Business Overview
6.1.3 Crown Bioscience Oncology Based Preclinical CRO Revenue, Global Share and Gross Margin (2020-2025)
6.1.4 Crown Bioscience Oncology Based Preclinical CRO Product Portfolio
6.1.5 Crown Bioscience Recent Developments
6.2 Charles River
6.2.1 Charles River Comapny Information
6.2.2 Charles River Business Overview
6.2.3 Charles River Oncology Based Preclinical CRO Revenue, Global Share and Gross Margin (2020-2025)
6.2.4 Charles River Oncology Based Preclinical CRO Product Portfolio
6.2.5 Charles River Recent Developments
6.3 ICON
6.3.1 ICON Comapny Information
6.3.2 ICON Business Overview
6.3.3 ICON Oncology Based Preclinical CRO Revenue, Global Share and Gross Margin (2020-2025)
6.3.4 ICON Oncology Based Preclinical CRO Product Portfolio
6.3.5 ICON Recent Developments
6.4 Eurofins Scientific
6.4.1 Eurofins Scientific Comapny Information
6.4.2 Eurofins Scientific Business Overview
6.4.3 Eurofins Scientific Oncology Based Preclinical CRO Revenue, Global Share and Gross Margin (2020-2025)
6.4.4 Eurofins Scientific Oncology Based Preclinical CRO Product Portfolio
6.4.5 Eurofins Scientific Recent Developments
6.5 Taconic Biosciences
6.5.1 Taconic Biosciences Comapny Information
6.5.2 Taconic Biosciences Business Overview
6.5.3 Taconic Biosciences Oncology Based Preclinical CRO Revenue, Global Share and Gross Margin (2020-2025)
6.5.4 Taconic Biosciences Oncology Based Preclinical CRO Product Portfolio
6.5.5 Taconic Biosciences Recent Developments
6.6 Covance
6.6.1 Covance Comapny Information
6.6.2 Covance Business Overview
6.6.3 Covance Oncology Based Preclinical CRO Revenue, Global Share and Gross Margin (2020-2025)
6.6.4 Covance Oncology Based Preclinical CRO Product Portfolio
6.6.5 Covance Recent Developments
6.7 EVOTEC
6.7.1 EVOTEC Comapny Information
6.7.2 EVOTEC Business Overview
6.7.3 EVOTEC Oncology Based Preclinical CRO Revenue, Global Share and Gross Margin (2020-2025)
6.7.4 EVOTEC Oncology Based Preclinical CRO Product Portfolio
6.7.5 EVOTEC Recent Developments
6.8 The Jackson Laboratory
6.8.1 The Jackson Laboratory Comapny Information
6.8.2 The Jackson Laboratory Business Overview
6.8.3 The Jackson Laboratory Oncology Based Preclinical CRO Revenue, Global Share and Gross Margin (2020-2025)
6.8.4 The Jackson Laboratory Oncology Based Preclinical CRO Product Portfolio
6.8.5 The Jackson Laboratory Recent Developments
6.9 MI Bioresearch
6.9.1 MI Bioresearch Comapny Information
6.9.2 MI Bioresearch Business Overview
6.9.3 MI Bioresearch Oncology Based Preclinical CRO Revenue, Global Share and Gross Margin (2020-2025)
6.9.4 MI Bioresearch Oncology Based Preclinical CRO Product Portfolio
6.9.5 MI Bioresearch Recent Developments
6.10 Champion Oncology
6.10.1 Champion Oncology Comapny Information
6.10.2 Champion Oncology Business Overview
6.10.3 Champion Oncology Oncology Based Preclinical CRO Revenue, Global Share and Gross Margin (2020-2025)
6.10.4 Champion Oncology Oncology Based Preclinical CRO Product Portfolio
6.10.5 Champion Oncology Recent Developments
6.11 Wuxi AppTec.
6.11.1 Wuxi AppTec. Comapny Information
6.11.2 Wuxi AppTec. Business Overview
6.11.3 Wuxi AppTec. Oncology Based Preclinical CRO Revenue, Global Share and Gross Margin (2020-2025)
6.11.4 Wuxi AppTec. Oncology Based Preclinical CRO Product Portfolio
6.11.5 Wuxi AppTec. Recent Developments
6.12 Xentech
6.12.1 Xentech Comapny Information
6.12.2 Xentech Business Overview
6.12.3 Xentech Oncology Based Preclinical CRO Revenue, Global Share and Gross Margin (2020-2025)
6.12.4 Xentech Oncology Based Preclinical CRO Product Portfolio
6.12.5 Xentech Recent Developments
6.13 Living Tumor Laboratory
6.13.1 Living Tumor Laboratory Comapny Information
6.13.2 Living Tumor Laboratory Business Overview
6.13.3 Living Tumor Laboratory Oncology Based Preclinical CRO Revenue, Global Share and Gross Margin (2020-2025)
6.13.4 Living Tumor Laboratory Oncology Based Preclinical CRO Product Portfolio
6.13.5 Living Tumor Laboratory Recent Developments
7 North America

7.1 North America Oncology Based Preclinical CRO Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
7.2 North America Oncology Based Preclinical CRO Market Size by Country (2020-2025)
7.3 North America Oncology Based Preclinical CRO Market Size Forecast by Country (2026-2031)
8 Europe

8.1 Europe Oncology Based Preclinical CRO Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
8.2 Europe Oncology Based Preclinical CRO Market Size by Country (2020-2025)
8.3 Europe Oncology Based Preclinical CRO Market Size Forecast by Country (2026-2031)
9 Asia-Pacific

9.1 Asia-Pacific Oncology Based Preclinical CRO Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
9.2 Asia-Pacific Oncology Based Preclinical CRO Market Size by Country (2020-2025)
9.3 Asia-Pacific Oncology Based Preclinical CRO Market Size Forecast by Country (2026-2031)
10 South America

10.1 South America Oncology Based Preclinical CRO Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
10.2 South America Oncology Based Preclinical CRO Market Size by Country (2020-2025)
10.3 South America Oncology Based Preclinical CRO Market Size Forecast by Country (2026-2031)
11 Middle East & Africa

11.1 Middle East & Africa Oncology Based Preclinical CRO Market Size Growth Rate (CAGR) by Country: 2020 VS 2024 VS 2031
11.2 Middle East & Africa Oncology Based Preclinical CRO Market Size by Country (2020-2025)
11.3 Middle East & Africa Oncology Based Preclinical CRO Market Size Forecast by Country (2026-2031)
12 Concluding Insights
13 Appendix

13.1 Reasons for Doing This Study
13.2 Research Methodology
13.3 Research Process
13.4 Authors List of This Report
13.5 Data Source
13.5.1 Secondary Sources
13.5.2 Primary Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings